Scarica l'app Stockscreener
1.16
1.75%
0.02
Precedente Chiudi:
$1.14
Aprire:
$1.17
Volume 24 ore:
269.07K
Relative Volume:
0.25
Capitalizzazione di mercato:
$17.49M
Reddito:
-
Utile/perdita netta:
$-11.24M
Rapporto P/E:
-1.5233
EPS:
-0.7615
Flusso di cassa netto:
$-4.79M
1 W Prestazione:
+11.54%
1M Prestazione:
+22.36%
6M Prestazione:
-38.95%
1 anno Prestazione:
+43.58%
Intervallo 1D:
$1.10
$1.19
Intervallo di 1 settimana:
$0.95
$1.21
Portata 52W:
$0.51
$5.01
Mira Pharmaceuticals Inc Stock (MIRA) Company Profile
Nome
Mira Pharmaceuticals Inc
Settore
Industria
Telefono
813-369-5150
Indirizzo
1200 BRICKELL AVENUE, MIAMI
Confronta MIRA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MIRA
Mira Pharmaceuticals Inc
|
1.16 | 17.49M | 0 | -11.24M | -4.79M | -0.7615 |
|
LLY
Lilly Eli Co
|
823.62 | 713.24B | 45.04B | 10.59B | 414.30M | 11.71 |
|
JNJ
Johnson Johnson
|
156.12 | 370.90B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
198.47 | 329.14B | 57.37B | 4.20B | 17.83B | 2.35 |
|
NVO
Novo Nordisk Adr
|
69.23 | 275.58B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
114.29 | 221.49B | 53.22B | 12.86B | 14.85B | 6.39 |
Mira Pharmaceuticals Inc Borsa (MIRA) Ultime notizie
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Short Interest Down 14.1% in April - Defense World
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
Mira Pharmaceuticals Inc [MIRA] moved up 7.08: Why It’s Important - dbtnews.com
Financial Metrics Unveiled: Mira Pharmaceuticals Inc (MIRA)’s Key Ratios in the Spotlight - DWinneX
MIRA Pharmaceuticals reports positive in vitro drug release data for topical Ketamir-2 - MSN
Mira Pharmaceuticals announces key drug development milestone By Investing.com - Investing.com Canada
Mira Pharmaceuticals announces key drug development milestone - Investing.com Australia
MIRA Pharmaceuticals (MIRA) Advances Ketamir-2 Formulations in P - GuruFocus
MIRA Pharmaceuticals reports positive Ketamir-2 study By Investing.com - Investing.com India
MIRA Pharmaceuticals reports positive Ketamir-2 study - Investing.com
MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation - Weatherford Democrat
Press Release Distribution & PR Platform - ACCESS Newswire
MIRA's Novel Pain Treatment Delivers Positive Data, Targets Massive $11.5B Market With Fast-Track Potential - Stock Titan
Mira Pharmaceuticals Inc (MIRA) is a good investment, but the stock may be undervalued - uspostnews.com
MIRA’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
Promising Canadian Stocks To Follow Now – April 16th - Defense World
Is Mira Pharmaceuticals Gaining or Losing Market Support? - Benzinga
US Health Care Stocks Face Mixed Results With Sector's Broad Decline - Finimize
Pharmaceutical Stock Jumps After Key Trial Findings - MSN
MIRA reports Ketamir-2 shows promise in diabetic neuropathy study By Investing.com - Investing.com South Africa
Mira Says Diabetes Treatment Ketamir-2 Shows Significant Reduction in Neuropathic Pain Symptoms in Animal Model - marketscreener.com
MIRA reports Ketamir-2 shows promise in diabetic neuropathy study - Investing.com Australia
MIRA Pharmaceuticals reports positive Ketamir-2 study results - Investing.com
MIRA Pharmaceuticals reports positive Ketamir-2 study results By Investing.com - Investing.com Canada
MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion - standard-journal.com
Game-Changing Results: New Oral Ketamine Drug Outperforms FDA-Approved Pain Medications - Stock Titan
Mira Pharmaceuticals IncAnnounces Positive Study Results For Ketamir-2 - marketscreener.com
EXCLUSIVE: MIRA Pharmaceuticals Ketamir-2 Shows Efficacy In Diabetes-Associated Nerve Damage In Animal Study - Benzinga
Mira Pharmaceuticals Inc’s Mixed Bag: Down -0.91% in 6 Months, Down -9.38% in 30 Days - investchronicle.com
Mira Pharmaceuticals faces Nasdaq delisting over equity - Investing.com Australia
Mira Pharmaceuticals faces Nasdaq delisting over equity By Investing.com - Investing.com South Africa
MIRA Mira Pharmaceuticals files $100M mixed securities shelf - MSN
Equities Analysts Issue Forecasts for MIRA FY2026 Earnings - Defense World
MIRA Pharmaceuticals begins Phase 1 trial for pain treatment - Investing.com Australia
MIRA Pharmaceuticals begins Phase 1 trial for pain treatment By Investing.com - Investing.com Philippines
MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain - guardonline.com
Game-Changing Pain Treatment Enters Clinical Trials: Superior to Current Options in Early Data - Stock Titan
63,410 Shares in MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Purchased by Virtu Financial LLC - Defense World
MIRA Pharmaceuticals (MIRA) Expected to Announce Earnings on Monday - Defense World
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Short Interest Up 38.9% in March - Defense World
MIRA Pharmaceuticals Inc. (MIRA) reports earnings - Quartz
MIRA Pharmaceuticals (NASDAQ:MIRA) Stock Price Down 4.3% – Here’s What Happened - Defense World
Mira Pharmaceuticals Inc Azioni (MIRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Mira Pharmaceuticals Inc Azioni (MIRA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Aminov Erez | Chief Executive Officer |
Nov 20 '24 |
Sale |
1.27 |
44,590 |
56,629 |
1,061,200 |
2.48%
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):